Cencora, Inc. (NYSE:COR – Get Free Report) Chairman Steven H. Collis sold 21,509 shares of the firm’s stock in a transaction on Tuesday, October 22nd. The shares were sold at an average price of $235.80, for a total value of $5,071,822.20. Following the completion of the transaction, the chairman now owns 285,088 shares in the company, valued at $67,223,750.40. The trade was a 0.00 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website.
Cencora Trading Down 0.3 %
NYSE COR opened at $234.47 on Friday. Cencora, Inc. has a 12 month low of $182.75 and a 12 month high of $247.66. The stock has a market capitalization of $46.77 billion, a P/E ratio of 25.65, a PEG ratio of 1.40 and a beta of 0.44. The firm’s 50-day moving average is $232.15 and its two-hundred day moving average is $230.87. The company has a debt-to-equity ratio of 3.93, a current ratio of 0.89 and a quick ratio of 0.55.
Cencora (NYSE:COR – Get Free Report) last posted its quarterly earnings data on Wednesday, July 31st. The company reported $3.34 earnings per share for the quarter, topping analysts’ consensus estimates of $3.18 by $0.16. Cencora had a net margin of 0.65% and a return on equity of 266.60%. The firm had revenue of $74.20 billion during the quarter, compared to analysts’ expectations of $73.32 billion. During the same quarter last year, the company posted $2.92 EPS. The firm’s quarterly revenue was up 10.8% on a year-over-year basis. On average, sell-side analysts anticipate that Cencora, Inc. will post 13.63 earnings per share for the current year.
Cencora Announces Dividend
Hedge Funds Weigh In On Cencora
Several hedge funds have recently bought and sold shares of the company. Lake Street Advisors Group LLC grew its position in Cencora by 1.3% in the 3rd quarter. Lake Street Advisors Group LLC now owns 3,415 shares of the company’s stock valued at $769,000 after acquiring an additional 43 shares in the last quarter. Financial Advocates Investment Management increased its stake in Cencora by 4.7% during the 2nd quarter. Financial Advocates Investment Management now owns 978 shares of the company’s stock worth $220,000 after buying an additional 44 shares during the period. Checchi Capital Advisers LLC lifted its holdings in Cencora by 2.2% during the 2nd quarter. Checchi Capital Advisers LLC now owns 2,217 shares of the company’s stock worth $499,000 after buying an additional 48 shares in the last quarter. J.W. Cole Advisors Inc. boosted its position in Cencora by 1.3% in the 3rd quarter. J.W. Cole Advisors Inc. now owns 3,669 shares of the company’s stock valued at $826,000 after buying an additional 48 shares during the period. Finally, Valeo Financial Advisors LLC grew its stake in shares of Cencora by 3.4% in the second quarter. Valeo Financial Advisors LLC now owns 1,566 shares of the company’s stock worth $353,000 after acquiring an additional 51 shares in the last quarter. Institutional investors and hedge funds own 97.52% of the company’s stock.
Analyst Ratings Changes
A number of equities analysts recently weighed in on the stock. Evercore ISI lowered their price target on shares of Cencora from $270.00 to $250.00 and set an “outperform” rating on the stock in a research report on Tuesday, October 8th. Robert W. Baird lowered their price objective on Cencora from $287.00 to $283.00 and set an “outperform” rating on the stock in a research note on Friday, September 6th. Leerink Partners cut their target price on Cencora from $277.00 to $275.00 and set an “outperform” rating for the company in a research note on Monday, October 7th. JPMorgan Chase & Co. boosted their price target on shares of Cencora from $280.00 to $287.00 and gave the company an “overweight” rating in a research report on Wednesday, August 21st. Finally, Bank of America restated a “neutral” rating and set a $245.00 price objective (down from $275.00) on shares of Cencora in a research report on Wednesday, September 18th. Three analysts have rated the stock with a hold rating and eight have issued a buy rating to the stock. According to data from MarketBeat, Cencora presently has an average rating of “Moderate Buy” and a consensus price target of $259.44.
Get Our Latest Analysis on Cencora
Cencora Company Profile
Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.
Further Reading
- Five stocks we like better than Cencora
- High Dividend REITs: Are They an Ideal Way to Diversify?
- Texas Roadhouse Stock Steering for New Highs This Year
- Why Invest in 5G? How to Invest in 5G Stocks
- Monopar Therapeutics Skyrockets 400% on Licensing Deal
- Using the MarketBeat Dividend Tax Calculator
- Tractor Supply Stock Pulls Back: A Prime Buying Opportunity
Receive News & Ratings for Cencora Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cencora and related companies with MarketBeat.com's FREE daily email newsletter.